Dr. Nikila V. Kumar, M.D.
Rheumatology (Rheumatology Physician)
4550 E Bell Rd Ste 170
Phoenix, AZ 85032
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- George Washington University School of Medicine (2012)
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 859
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Medical school: George Washington University School of Medicine
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
AZ license 50980
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Arizona Arthritis and Rheumatology Associates P C (65 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 859
- Services billed
- 198,985
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, tocilizumab, 1 mg | 81,436 | 31 |
| Injection, golimumab, 1 mg, for intravenous use | 33,086 | 70 |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 29,800 | 15 |
| Injection, denosumab, 1 mg | 24,960 | 277 |
| Injection, romosozumab-aqqg, 1 mg | 21,630 | 35 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 16,025 | 38 |
| Injection, infliximab, excludes biosimilar, 10 mg | 5,711 | 35 |
| Injection, rituximab, 10 mg | 5,000 | 15 |
| Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | 3,044 | 18 |
| Insertion of needle into vein for collection of blood sample | 1,594 | 734 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Methotrexate (methotrexate sodium) Other prescribers in Phoenix, AZ | 363 |
| Hydroxychloroquine Sulfate Other prescribers in Phoenix, AZ | 198 |
| Prednisone Other prescribers in Phoenix, AZ | 182 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Phoenix, AZ | 82 |
| Xeljanz Xr (tofacitinib citrate) | 61 |
| Folic Acid Other prescribers in Phoenix, AZ | 60 |
| Gabapentin Other prescribers in Phoenix, AZ | 58 |
| Enbrel Mini (etanercept) Other prescribers in Phoenix, AZ | 55 |
| Allopurinol Other prescribers in Phoenix, AZ | 52 |
| Enbrel Sureclick (etanercept) Other prescribers in Phoenix, AZ | 49 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 184 payments worth $3,248 in total to this clinician.
| AbbVie Inc. | $912 |
|---|---|
| UCB, Inc. | $536 |
| Amgen Inc. | $422 |
| Pfizer Inc. | $277 |
| Janssen Biotech, Inc. | $239 |
| E.r. Squibb & Sons, L.l.c. | $136 |
| Novartis Pharmaceuticals Corporation | $122 |
| Radius Health, Inc. | $119 |
| Food and Beverage | $3,248 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 4 companies. The companies reported $1,979,816 in research payments for these studies, mostly to the institutions running them.
- A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants
Amgen Inc. - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
AbbVie Inc. · Completed · NCT05814627 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
AbbVie Inc. · Active, not recruiting · NCT05843643 - A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis
Janssen Research & Development, LLC - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
AbbVie Inc. · Active, not recruiting · NCT02629159 - Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
Janssen Research & Development, LLC - A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease
Janssen Research & Development, LLC - A Multicenter Randomized Double blind Placebo controlled Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus and Refractory and/or In…
AstraZeneca UK Limited - M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
AbbVie Inc. - M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.